Pulmonary vascular disease & thromboembolismDiagnostic or prognostic study
Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension
- Prognostic cohort study
- 2 national centres
- discovery and validation cohorts
Authors' conclusion
Plasma IgG fucosylation informs PAH prognosis independent of established factors, offering additional value for predicting PAH outcomes.
Study context
- Population
- Patients with pulmonary arterial hypertension (PAH)
- Participants
- 622 patients
- Comparison
- Beijing vs Shanghai
- Beijing (discovery)n = 273
- Shanghai (validation)n = 349
- Outcome
- Survival (mortality) predicted by plasma IgG N-glycan traits
Performance
As reported in the abstract
Plasma IgG fucosylation and survival, adjusted for age and sex
IgG fucosylationHazard ratio (95% CI)P value
discovery cohort
0.377(0.168–0.845)
P = 0.018validation cohort
0.445(0.264–0.751)
P = 0.005Further findings
Mortality, combined cohorts
- Immunoglobulin G (IgG) fucosylation remained a robust predictor after full adjustment and in subgroup analyses
Added value to established risk models (Harrell C-index)
- Adding IgG fucosylation improved predictive capacity, with overall elevation in Harrell C-indexes
- Further stratified intermediate-risk patients of an established model
Original publication
Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension. J Am Coll Cardiol. Published 17 September 2024. doi:10.1016/j.jacc.2024.05.077
Summarised from the published abstract; every number is checked against it